Global Cancer Vaccines Market Trends, Analysis, Growth, and Forecast to 2027

MarketResearch.biz delivers in-depth insights on the global cancer vaccines market in its upcoming report titled, “Global Cancer Vaccines Market Trends, Applications, Analysis, Growth, and Forecast to 2027”. The global cancer vaccines market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the target market, and the various trends, drivers, restraints, opportunities, and threats till 2026. The report offers insightful and detailed information regarding the various key players operating in the market, their financials, supply chain trends, technological innovations, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global cancer vaccines market report has been segmented on the basis of treatment method, type, application, and region.

Vaccines can be used in treatment of cancer as it can recognize protein that are present on particular cancer cells. Cancer vaccines provides numerous benefits as it can stop the growth of cancerous cells, prevents cancer relapse and destroy cancer cells that are left behind after other treatment. Many different types of vaccine are used for the treatment of cancer such as antigen vaccines which boost the immune systems instead of using whole tumor cells and can be targeted to specific cancer type. Vector based vaccines can be used to deliver more than one cancer antigen at a time.

Increasing incidence of cancer such as breast cancer, prostate cancer, and lung cancer globally is expected to fuel the growth of global cancer vaccines market over the forecast period. Continuous development by manufacturers for development of new vaccines is expected to boost the growth of global cancer vaccines market over the forecast period.

High cost and time incurred in development of cancer vaccine are factors restraining the growth of market over the forecast period.

However, technological advancements and innovations focusing on development of specific and effective cancer treatment is expected to create new opportunities for major players in the global cancer vaccines market over the forecast period.

North America market dominates the global cancer vaccines market in terms of revenue contribution as compared to that of markets in other regions. This is attributed to the presence of dominant players in the market and well developed healthcare infrastructure in the region. Europe accounts for second-largest revenue share contribution to the global cancer vaccines market, followed by markets in the Asia Pacific, Latin America, and the Middle East & Africa respectively. The market in the Asia Pacific is projected to register comparatively faster growth in terms of revenue over the next 10 years owing to increasing incidence of cancer in the region.

Global cancer vaccines market segmentation;

By treatment method:

• Preventive cancer vaccines
• Therapeutic cancer vaccines

 By type:

• Subunit Vaccines
• Live Attenuated Vaccines
• Conjugate Vaccines
• Inactivated Vaccines
• Recombinant Vector Vaccines
• Viral Vector and DNA Vaccines
• Others

 By application:

• Cervical cancer
• Prostate cancer
• Lung cancer
• Breast cancer
• Others

By region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Astrazeneca plc.
• Glaxosmithkline Plc.
• Merck & Co., Inc.
• Aduro BioTech Inc.
• Prima BioMed
• Pfizer Inc.
• Serum Institute of India Pvt. Ltd.
• Sanofi SA
• Gritstone Oncology, Inc.
• PaxVax Corporation